A new pharmacological therapy for the mitochondrial disease Leigh syndrome
|Coordinator||NeuroVive Pharmaceutical AB|
|Funding from Vinnova||SEK 5 000 000|
|Project duration||November 2018 - November 2020|
|Venture||SWElife Phase 2 2017|
Purpose and goal
The project objective is to develop a new pharmacological therapy for chronic oral treatment of patients with the mitochondrial disease Leigh syndrome. Leigh syndrome is a severe inherited genetic mitochondrial disease primarily affecting the central nervous system and other organ systems with high energy requirements. It usually presents in the first year of life, and is normally fatal within a few years. There are no pharmacological therapies available for Leigh syndrome and related disorders.
Expected results and effects
Most cases of Leigh syndrome are due to dysfunction in complex I (CI) of the mitochondrial electron transport system. The drug compound we develop in this project is specifically targeting this dysfunction. A drug targeting Leigh syndrome could ameliorate clinical progression of disease, reduce morbidity, and decrease mortality in this patient group. Subsequently NV354 has the potential to receive approval for use in other mitochondrial diseases, thereby serving a much broader patient population.
Planned approach and implementation
The team will progress the project through TRL5 and prepare it for IND/CTA application and Phase I first-in-human clinical trials. The project will also include activities in order to have a clinical stage candidate drug with a solid business case. Important relationships have been built with key academic investigators, KOLs, care givers and patient organisations which will be further strengthened.